Elevated intracranial pressure and brain herniation

Intracranial pressure (ICP) is the pressure that exists within the cranium, including its compartments (e.g., the subarachnoid space and the ventricles). ICP varies as the position of the head changes relative to the body and is periodically influenced by normal physiological factors (e.g., cardiac contractions). Adults in the supine position typically have a physiological ICP of ≤ 15 mm Hg; an ICP of ≥ 20 mm Hg indicates pathological intracranial hypertension. ICP may be elevated in a variety of conditions (e.g., intracranial tumors) and can result in a decrease in cerebral perfusion pressure (CPP) and/or herniation of cerebral structures. Symptoms of elevated ICP are generally nonspecific (e.g., impaired consciousness, headache, vomiting); however, more specific symptoms may be present depending on the affected structures (e.g., Cushing triad if the brainstem is compressed). Findings from brain imaging (e.g., a midline shift) and physical examination (e.g., papilledema) can indicate ICP elevation, but may not be able to rule it out. Therefore, ICP monitoring and quantification are vital in at-risk patients. Management usually involves expedited surgery of resectable or drainable lesions, conservative measures (e.g., positioning, sedation, analgesia, and antipyretics), and medical therapy (e.g., hyperosmolar therapy such as mannitol or hypertonic saline, or glucocorticoids). Treatment options for refractory intracranial hypertension include temporary controlled hyperventilation, CSF drainage, and decompressive craniectomy (DC), as well as other advanced medical therapies (e.g., barbiturate coma, therapeutic hypothermia).

• Idiopathic intracranial hypertension
• CNS inflammation, infection, and/or abscess
• Space-occupying lesions
  • Intracranial hemorrhage or hematoma
  • Aneurysm
  • Intracranial tumors
• Elevated venous pressure (e.g., as a result of heart failure)
• Increased CSF (hydrocephalus)
• Metabolic disturbances; (e.g., hyponatremia, hepatic encephalopathy)
• Epilepsy and seizures ^[1]

Physiology

• Physiological ICP is ≤ 15 mm Hg in adults (in supine position); children generally have a lower ICP.
• ICP varies as the position of the head changes relative to the body and is influenced by certain physiological processes (e.g., cardiac contractions, sneezing, coughing, Valsalva maneuver).
• Expansion of either blood, CSF, or tissue within the skull → limited capacity for the intracranial volume to increase within the rigid skull → increase in intracranial pressure

Consequences of elevated ICP

• Decreased cerebral perfusion pressure (CPP)
  • CPP is the effective pressure that delivers blood to the cerebral tissue.
  • CPP = mean arterial pressure - ICP
  • Therefore, if the ICP rises, the CPP diminishes (as long as the arterial pressure remains constant).
• Brain tissue herniation
  • As a bony structure, the skull is rigid and cannot expand to compensate elevated internal pressure.
  • Increased pressure gradient within the skull in the presence of inflexible brain structures (e.g., tentorium cerebelli) → flexible brain tissue shifts → possible brain tissue herniation
  • This may result in direct physical damage or in blocking of cerebral vessels and subsequent ischemia.
• Cushing triad: also called Cushing reflex or Cushing response and is thought to reflect brainstem compression. This sign indicates a need for urgent treatment.
  • ↑ Intracranial pressure → ↓ perfusion pressure within the brain → compensatory activation of the sympathetic nervous system to maintain cerebral perfusion → ↑ systolic blood pressure → stimulation of aortic arch baroreceptors → activation of the parasympathetic nervous system (vagus) → bradycardia ^[2]
  • ↑ Pressure on brainstem → dysfunction of respiratory center → irregular breathing

• Global
  • Cushing triad: irregular breathing, widening pulse pressure, and bradycardia
  • Reduced levels of consciousness
  • Headache
  • Vomiting
  • Papilledema
  • Psychiatric changes
  • In infants: macrocephaly, bulging fontanel, sunset sign
• Focal
  • Diplopia
  • Cerebral herniation syndrome: see “Subtypes and variants” below.

Cerebral herniation syndromes

• Subfalcine herniation: cingulate gyrus of one hemisphere is compressed and herniates under the falx cerebri → compression of:
  • Contralateral hemisphere → obstruction of the foramen of Monro → hydrocephalus
  • Pericallosal arteries → hemiparesis (predominantly lower limbs)
• Uncal herniation: medial temporal lobe (the uncus) herniates at the tentorial incisure
  • Compression of:
    • Ipsilateral oculomotor nerve palsy → fixed and dilated pupil
    • Ipsilateral posterior cerebral artery → cortical blindness with contralateral homonymous hemianopia
    • Contralateral cerebral peduncle → ipsilateral paralysis + Kernohan phenomenon: a paradoxical ipsilateral weakness (due to contralateral cerebral peduncle compression). This is unusual because commonly, an ipsilateral brain lesion results in contralateral motor symptoms. It occurs in patients with increased ICP caused by intracranial hemorrhage or cerebral edema.)
  • Downward shift of the brainstem → brainstem hemorrhages → focal deficits, impaired consciousness, death
• Foramen magnum herniation: structures of the posterior fossa (e.g., cerebellar tonsils, medulla) herniate at the foramen magnum → impaired consciousness, decerebrate posturing, apnea, impaired circulation, death

The following clinical features should raise suspicion for a cerebral herniation syndrome, which can be fatal if not treated promptly: acutely worsening level of consciousness (e.g., coma), pupillary changes (e.g., ipsilateral mydriasis, fixed dilated pupils), new focal neurological deficits (e.g., hemiparesis, decerebrate posturing), and cardiorespiratory compromise (e.g., bradycardia, apnea).

References:^[3][4]

Neuroimaging (CT head/MRI head) ^[5]

• Indications
  • Clinical features of increased ICP
  • Suspected intracerebral pathology: e.g., neurological compromise, seizures, head trauma
  • See also “Diagnostics in TBI.”
• Neuroimaging findings of intracranial hypertension: indirect indicators of elevated ICP and cerebral edema
  • Midline shift
  • Mass lesions
    • TBIs: e.g., EDH, SDH, ICH, parenchymal contusions
    • CNS infections: e.g., brain abscess
    • Brain tumors (with or without surrounding vasogenic edema)
  • Effacement of the basilar cisterns
  • Effacement of cerebral sulci
  • Evidence of brain herniation (e.g., uncal herniation or tonsillar herniation)
  • Changes in ventricular size (e.g., enlarged with hydrocephalus, reduced with diffuse cerebral edema)

Clinical examination and imaging may indicate elevated ICP, but cannot rule it out. Additionally, neither allow ICP to be quantified, which is necessary to determine CPP.

Invasive ICP monitoring

• Invasive monitoring is typically required for confirmation and accurate measurement of ICP.
• ICP should be evaluated in combination with CPP to guide therapeutic interventions and help prevent secondary brain injury and brain herniation. ^[6]
• There are no absolute contraindications for invasive ICP monitoring.
• Consider the risks versus the benefits in consultation with a specialist.

Indications ^[7][8][9]

• Traumatic brain injury: ICP monitoring in severe TBI reduces in-hospital and two-week postinjury mortality. ^[8]
• Mass lesions: e.g., brain tumors, ICH, SAH, SDH, EDH
• Diffuse brain injury due to:
  • Infectious causes: e.g., meningitis, encephalitis
  • Vascular causes: e.g., ischemic stroke, cerebral venous thrombosis
  • Other causes: e.g., hydrocephalus, idiopathic intracranial hypertension
• Other: nonsurgical intracranial hemorrhages in patients who cannot undergo full clinical evaluation

Methods to monitor ICP ^[6][10][11]

Intraventricular catheters; with an external ventricular drain (EVD) and intraparenchymal catheters; (IPC) are most commonly used to monitor ICP, as they have the highest accuracy compared with other monitoring methods.

• Intraventricular catheter: a monitoring device placed into the ventricles of the brain along with a CSF drainage system (i.e., an EVD) ^[12]
  • Allows for continuous ICP monitoring and evaluation of intracranial compliance
  • Useful in conditions in which CSF drainage is required for both diagnostic and therapeutic purposes
  • The preferred monitoring method for intracranial lesions associated with hydrocephalus ^[6]
  • Complications
    • Infections
    • Hemorrhage attributable to the placement of the device
    • Malpositioning and/or accidental removal
    • Blockage with blood or debris
• Intraparenchymal catheter: a fiberoptic device placed into the brain parenchyma without an accompanying CSF drainage system ^[13]
  • Allows for continuous ICP monitoring
  • Accuracy and effect on patient outcomes are considered equivalent to intraventricular catheters
  • Lower risk of infection and hemorrhage compared with intraventricular catheters
  • Technical complications: e.g., dislodgement, breakage

Interpretation

• Generally, ICP > 20 mm Hg indicates intracranial hypertension, which requires treatment. ^[6]
• ICP varies in a complex cyclical manner and is influenced by hemodynamic and metabolic factors.
• Monitor ICP along with MAP to calculate CPP using the formula CPP = MAP − ICP.

Do not use the ICP value in isolation as a prognostic marker or to inform therapeutic decisions. ^[6]

Approach ^{[5][6][8][14][15][16]}

• Indications for ICP management
  • Clinical or radiographic signs of elevated ICP
  • Confirmed elevated ICP on direct measurement
• Goals: Maintain cerebral blood flow (CBF) and prevent secondary brain injury.
• Acute resuscitation and stabilization: Follow the ABCDE approach.
  • Emergency airway management (e.g., if GCS < 8): high-risk, as laryngeal manipulation can raise ICP (see “Intubation of patients with increased ICP”)
  • Mechanical ventilation as needed: See “Ventilation strategy for elevated ICP.”
  • Hemodynamic support: See “Shock.”
• Consultation: Early involvement of neurosurgery and a neurocritical care specialist is essential.

• General therapeutic targets: Base treatment decisions on trends identified using repeat assessments of ICP, CPP, and clinical status. ^[6][8]
  • Target ICP: < 20 mm Hg
  • Target CPP range: 60–70 mm Hg

Conservative therapy ^[19]

See also “Neuroprotective measures.”

• Patient positioning ;:
  • Head of bed elevation (∼ 30°): ^[14][20]
    • Reduces ICP without compromising CBF
    • Blunts the effect of high PEEP on ICP
    • Should be avoided if the patient is _Definitions"#Z2c4b7b192fbfa8d2679ddc134ed0e9c5" data-lxid="Ig0Y92">hypovolemic
  • Avoid neck flexion and rotation and situations that may provoke a Valsalva response.
• Sedation and analgesia ^[14]
  • Prevents unnecessary spikes in ICP due to pain, agitation, and patient-ventilator dyssynchrony
  • Combinations of benzodiazepines, opioid analgesics, and dexmedetomidine are generally used.
  • Ketamine was previously contraindicated, but recent evidence suggests that it may be suitable for use.
  • Propofol may be used but caution should be taken when using high doses because of the risk of hypotension. ^[8]
  • Minimize waking patients up for neurological assessments.^[6][20]
  • See “Adjunctive care of ventilated patients” for dosages and further information.
• Temperature management: : Maintain normothermia; fever should be treated with antipyretics.
• Fluid management: Target euvolemia and avoid serum hypoosmolarity.
• Seizure control
  • Administer antiepileptics as needed for patients who are experiencing seizures or those at high risk of seizures.
  • Routine seizure prophylaxis is not recommended.

Medical therapy ^[19]

• Hyperosmolar therapy
  • Indications
    • Elevated ICP refractory to conservative measures
    • Empiric therapy for patients with elevated ICP and herniation syndrome or neurological deterioration ^[8]
  • Options ^[21][22][23]
    • IV hypertonic saline (HTS) ^[24][25]
    • IV mannitol

Although hyperosmolar therapies can lower ICP, they have not been shown to improve neurological outcomes in patients with underlying TBI, acute ischemic stroke, ICH, SAH, or hepatic encephalopathy. ^[19]

• Glucocorticoids: e.g., dexamethasone
  • Recommended only if elevated ICP is caused by vasogenic edema secondary to: ^[16][31]
    • CNS infection or inflammation (e.g., bacterial or tuberculous meningitis) ^[19]
    • Neoplasms
  • Avoid in patients with ICH. ^[19]
  • Not recommended in large hemispheric stroke ^[20]
  • Contraindicated in TBI (associated with increased mortality) ^[8]

Surgical therapy

• Emergency surgery (if possible): e.g., resection of brain tumor, hematoma evacuation ^[16]
• CSF drainage
  • Indications ^[18]
    • Acute obstructive hydrocephalus (can be caused by TBI, ICH, and ischemic stroke)
    • Diffuse cerebral edema
    • Intracranial lesion causing mass effect
  • Options
    • External ventricular drain ^[12]
      • Can be inserted at the bedside or in the operating room by a neurosurgeon or other trained clinician
      • Drainage of 1–2 mL of CSF reduces ICP temporarily. ^[14]
    • Lumbar drain
    • Cerebral shunt
  • Risks: hemorrhage, infection (e.g., ventriculitis, encephalitis, meningitis)
• Decompressive craniectomy (DC): removal of a portion of the skull, which allows the brain to expand in volume, thereby reducing ICP ^[32]
  • Primary DC: removal of a skull flap following evacuation or resection of an intracranial lesion (e.g., brain tumor)
  • Secondary DC: removal of a skull flap without additional surgical procedures to treat refractory elevated ICP
    • Recommended for (controversial): ^[32]
      • Late refractory elevated ICP: reduced mortality, improved outcomes
      • Early or late refractory elevated ICP: improved control of ICP, reduced neuro-ICU length of stay
      • Large hemispheric stroke (e.g., malignant MCA infarction) in patients with an infarct > 12 cm and within 24–48 hours of symptom onset ^[20][33]
    • Not recommended for patients with early refractory elevated ICP
  • Multiple approaches have been described in the literature (suboccipital, subtemporal, frontotemporoparietal, etc.) depending on the type and location of the brain lesion. ^[34]
  • Lowers mortality in TBI without improving neurological or functional outcomes ^[15]

Nonsurgical therapy for refractory intracranial hypertension ^[19]

Controlled hyperventilation

Hyperventilation is primarily used as a temporizing measure for intracranial hypertension refractory to medical therapy. ^[17]

• Indications ^[35]
  • Bridge to surgical therapy for expanding lesions (e.g., intracranial hemorrhages)
  • Treatment of life-threatening elevated ICP pending investigation results and onset of action of medical therapy (e.g., hyperosmolar therapy)
• Therapeutic targets
  • First 30 minutes: PaCO₂ 30–35 mm Hg ^[35]
  • After 30 minutes: normocapnia, i.e., PaCO₂ 35–45 mm Hg (see “Ventilation strategy for elevated ICP”)

Controlled hyperventilation should only be used short-term and is not recommended routinely or for prophylaxis. Avoid excessive hyperventilation (PaCO₂ < 30 mm Hg), prolonged hyperventilation, and hypoventilation of any kind, as CBF and perfusion may become compromised.

Advanced therapies

These are primarily reserved for patients with persistently refractory intracranial hypertension.

• Barbiturate coma: e.g., pentobarbital (off-label, not routinely recommended) ^[14][36][37]
  • Not recommended in patients with large hemispheric stroke ^[20]
  • Adverse effects: e.g., hypotension, hypokalemia, infection, multiorgan dysfunction ^[14]
• Therapeutic hypothermia: highly controversial ^{[10][38][39][40][41][42][43]}
  • No benefit has been observed when used prophylactically ^[10]
  • Not recommended in TBI ^[8][39]

• Irreversible loss of brain function (brain death)

Cerebral edema

• Definition: excess accumulation of fluid within the brain parenchyma as a result of damage to the blood-brain barrier and/or the blood-CSF barrier ^[44]
  • Vasogenic: extracellular accumulation of fluids as a result of impaired capillary permeability secondary to breakdown of endothelial tight junctions
  • Cytotoxic: intracellular accumulation of fluids as a result of impaired Na⁺/K⁺-ATPase function
  • Interstitial: interstitial (therefore extracellular) accumulation of fluids as a result of increased CSF influx into the brain parenchyma (which is itself due to blocked CSF drainage)
• Etiology
  • Cerebral infarction (stroke)
  • Iatrogenic (Rapid lowering of glucose or rapid correction of hypernatremia)
  • Trauma (particularly in closed head injury)
  • Toxic (e.g., lead intoxication) ^[45]
  • Inflammatory (e.g., meningitis)
  • Space-occupying lesions (e.g., brain tumors, intracranial hemorrhage)
• Management: treatment of raised ICP

We list the most important complications. The selection is not exhaustive.

1. American College of Surgeons and the Committee on Trauma. ATLS Advanced Trauma Life Support. American College of Surgeons ; 2018
2. Hackett JG, Abboud FM, Mark AL, Schmid PG, Heistad DD. Coronary vascular responses to stimulation of chemoreceptors and baroreceptors: evidence for reflex activation of vagal cholinergic innervation. Circ Res. 1972; 31 (1): p.8-17.
3. Shah AK, Fuerst D, Sood S et al. Seizures Lead to Elevation of Intracranial Pressure in Children Undergoing Invasive EEG Monitoring. Epilepsia. 2017; 48 (6): p.1097-1103. doi: 10.1111/j.1528-1167.2006.00975.x . | Open in Read by QxMD
4. Goetz CG. Textbook of Clinical Neurology. Elsevier ; 2007
5. Herniation Syndromes. http://casemed.case.edu/clerkships/neurology/NeurLrngObjectives/Herniation%20syndromes.htm. Updated: July 17, 2006. Accessed: March 1, 2017.
6. Walls R, Hockberger R, Gausche-Hill M. Rosen's Emergency Medicine. Elsevier Health Sciences ; 2018
7. Changa AR, Czeisler BM, Lord AS. Management of Elevated Intracranial Pressure: a Review. Curr Neurol Neurosci Rep. 2019; 19 (12): p.99. doi: 10.1007/s11910-019-1010-3 . | Open in Read by QxMD
8. Le Roux P, Menon DK, Citerio G, et al. Consensus Summary Statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care. Neurocrit Care. 2014; 21 (S2): p.1-26. doi: 10.1007/s12028-014-0041-5 . | Open in Read by QxMD
9. Wagner KE et al.. Trauma. Oper Neurosurg. 2019; 17 (Supplement_1): p.S45-S75. doi: 10.1093/ons/opz089 . | Open in Read by QxMD
10. Carney N, Totten AM, O’Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2016; 80 (1): p.6-15. doi: 10.1227/neu.0000000000001432 . | Open in Read by QxMD
11. Kristiansson H et al.. Measuring Elevated Intracranial Pressure through Noninvasive Methods. J Neurosurg Anesthesiol. 2013; 25 (4): p.372-385. doi: 10.1097/ana.0b013e31829795ce . | Open in Read by QxMD
12. Dimitriou J et al.. Comparison of Complications in Patients Receiving Different Types of Intracranial Pressure Monitoring: A Retrospective Study in a Single Center in Switzerland. World Neurosurg. 2016; 89 : p.641-646. doi: 10.1016/j.wneu.2015.11.037 . | Open in Read by QxMD
13. Fried HI, Nathan BR, Rowe AS, et al. The Insertion and Management of External Ventricular Drains: An Evidence-Based Consensus Statement. Neurocrit Care. 2016; 24 (1): p.61-81. doi: 10.1007/s12028-015-0224-8 . | Open in Read by QxMD
14. Volovici V, Huijben JA, Ercole A, et al. Ventricular Drainage Catheters versus Intracranial Parenchymal Catheters for Intracranial Pressure Monitoring-Based Management of Traumatic Brain Injury: A Systematic Review and Meta-Analysis. J Neurotrauma. 2019; 36 (7): p.988-995. doi: 10.1089/neu.2018.6086 . | Open in Read by QxMD
15. Winn HR. Youmans and Winn Neurological Surgery. Elsevier ; 2016
16. Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension. N Engl J Med. 2016; 375 (12): p.1119-1130. doi: 10.1056/nejmoa1605215 . | Open in Read by QxMD
17. Esquenazi Y, Lo VP, Lee K. Critical Care Management of Cerebral Edema in Brain Tumors. J Intensive Care Med. 2016; 32 (1): p.15-24. doi: 10.1177/0885066615619618 . | Open in Read by QxMD
18. Rabinstein AA et al. Neurological Emergencies. Springer International Publishing ; 2020
19. Schizodimos T, Soulountsi V, Iasonidou C, Kapravelos N. An overview of management of intracranial hypertension in the intensive care unit. J Anesth. 2020; 34 (5): p.741-757. doi: 10.1007/s00540-020-02795-7 . | Open in Read by QxMD
20. Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020; 32 (3): p.647-666. doi: 10.1007/s12028-020-00959-7 . | Open in Read by QxMD
21. Torbey MT, Bösel J, Rhoney DH, et al. Evidence-Based Guidelines for the Management of Large Hemispheric Infarction. Neurocrit Care. 2015; 22 (1): p.146-164. doi: 10.1007/s12028-014-0085-6 . | Open in Read by QxMD
22. Burgess S, Abu-Laban RB, Slavik RS, Vu EN, Zed PJ. A Systematic Review of Randomized Controlled Trials Comparing Hypertonic Sodium Solutions and Mannitol for Traumatic Brain Injury. Ann Pharmacother. 2016; 50 (4): p.291-300. doi: 10.1177/1060028016628893 . | Open in Read by QxMD
23. Miyoshi Y, Kondo Y, et al. Effects of hypertonic saline versus mannitol in patients with traumatic brain injury in prehospital, emergency department, and intensive care unit settings: a systematic review and meta-analysis. Journal of Intensive Care. 2020; 8 (1). doi: 10.1186/s40560-020-00476-x . | Open in Read by QxMD
24. Chen H, Song Z, Dennis JA. Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury. Cochrane Database of Systematic Reviews. 2020 . doi: 10.1002/14651858.cd010904.pub3 . | Open in Read by QxMD
25. Quintard H, Meyfroidt G, Citerio G. Hyperosmolar Agents for TBI: All Are Equal, But Some Are More Equal Than Others?. Neurocrit Care. 2020; 33 (2): p.613–614. doi: 10.1007/s12028-020-01063-6 . | Open in Read by QxMD
26. Cook AM, Shutter L. Response to Drs. Quintard, et al.. Neurocrit Care. 2020; 33 (2): p.615-616. doi: 10.1007/s12028-020-01064-5 . | Open in Read by QxMD
27. Rowland MJ, Veenith T, Hutchinson PJ, Perkins GD. Osmotherapy in traumatic brain injury. The Lancet Neurology. 2020; 19 (3): p.208. doi: 10.1016/s1474-4422(20)30003-x . | Open in Read by QxMD
28. Mangat HS. Hypertonic saline infusion for treating intracranial hypertension after severe traumatic brain injury. Critical Care. 2018; 22 (1): p.37. doi: 10.1186/s13054-018-1963-7 . | Open in Read by QxMD
29. Boone M, Oren-Grinberg A, Robinson T, Chen C, Kasper E. Mannitol or hypertonic saline in the setting of traumatic brain injury: What have we learned?. Surgical Neurology International. 2015; 6 (1): p.177. doi: 10.4103/2152-7806.170248 . | Open in Read by QxMD
30. Wagner I, Hauer E-M, Staykov D, et al. Effects of Continuous Hypertonic Saline Infusion on Perihemorrhagic Edema Evolution. Stroke. 2011; 42 (6): p.1540-1545. doi: 10.1161/strokeaha.110.609479 . | Open in Read by QxMD
31. Wells DL, Swanson JM, Wood GC, et al. The relationship between serum sodium and intracranial pressure when using hypertonic saline to target mild hypernatremia in patients with head trauma. Critical Care. 2012; 16 (5): p.R193. doi: 10.1186/cc11678 . | Open in Read by QxMD
32. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96 (1): p.103-114. doi: 10.1007/s11060-009-0057-4 . | Open in Read by QxMD
33. Hawryluk GWJ, Rubiano AM, Totten AM, et al. Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations. Neurosurgery. 2020; 87 (3): p.427-434. doi: 10.1093/neuros/nyaa278 . | Open in Read by QxMD
34. Honeybul S, Ho KM, Gillett G. Outcome Following Decompressive Hemicraniectomy for Malignant Cerebral Infarction. Stroke. 2015; 46 (9): p.2695-2698. doi: 10.1161/strokeaha.115.010078 . | Open in Read by QxMD
35. Bullock MR, Chesnut R, Ghajar J, et al. Guidelines for the Surgical Management of Traumatic Brain Injury Author Group. Neurosurgery. 2006; 58 (3): p.S2-vi-S2-vi. doi: 10.1093/neurosurgery/58.3.vi . | Open in Read by QxMD
36. Godoy DA, Seifi A, Garza D, Lubillo-Montenegro S, Murillo-Cabezas F. Hyperventilation Therapy for Control of Posttraumatic Intracranial Hypertension. Frontiers in Neurology. 2017; 8 : p.250. doi: 10.3389/fneur.2017.00250 . | Open in Read by QxMD
37. Clark J, Ellens N, Figueroa B. The use of barbiturate-induced coma during cerebrovascular neurosurgery procedures: A review of the literature. Brain Circulation. 2015; 1 (2): p.140. doi: 10.4103/2394-8108.172887 . | Open in Read by QxMD
38. Roberts I, Sydenham E. Barbiturates for acute traumatic brain injury. Cochrane Database of Systematic Reviews. 2012 : p.CD000033. doi: 10.1002/14651858.cd000033.pub2 . | Open in Read by QxMD
39. Crompton EM, Lubomirova I, Cotlarciuc I, Han TS, Sharma SD, Sharma P. Meta-Analysis of Therapeutic Hypothermia for Traumatic Brain Injury in Adult and Pediatric Patients. Crit Care Med. 2017; 45 (4): p.575-583. doi: 10.1097/ccm.0000000000002205 . | Open in Read by QxMD
40. Andrews PJ, Sinclair HL, Rodríguez A, et al. Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT. Health Technol Assess (Rockv). 2018; 22 (45): p.1-134. doi: 10.3310/hta22450 . | Open in Read by QxMD
41. Watson HI, Shepherd AA, Rhodes JKJ, Andrews PJD. Revisited: A Systematic Review of Therapeutic Hypothermia for Adult Patients Following Traumatic Brain Injury. Crit Care Med. 2018; 46 (6): p.972-979. doi: 10.1097/ccm.0000000000003125 . | Open in Read by QxMD
42. Andrews et al.. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. New England Journal of Medicine. 2015; 373 (25): p.2403-2412. doi: 10.1056/nejmoa1507581 . | Open in Read by QxMD
43. Chen H, Wu F, Yang P, Shao J, Chen Q, Zheng R. A meta-analysis of the effects of therapeutic hypothermia in adult patients with traumatic brain injury. Critical Care. 2019; 23 (1): p.396. doi: 10.1186/s13054-019-2667-3 . | Open in Read by QxMD
44. Karnatovskaia LV, Lee AS, Festic E, Kramer CL, Freeman WD. Effect of Prolonged Therapeutic Hypothermia on Intracranial Pressure, Organ Function, and Hospital Outcomes Among Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2014; 21 (3): p.451-461. doi: 10.1007/s12028-014-9989-4 . | Open in Read by QxMD
45. Marmarou A. A review of progress in understanding the pathophysiology and treatment of brain edema. Neurosurg Focus. 2007; 22 (5): p.E1.
46. Rao JVI, Vengamma B, Naveen T, Naveen V. Lead encephalopathy in adults. J Neurosci Rural Pract. 2014; 5 (2): p.161-163. doi: 10.4103/0976-3147.131665 . | Open in Read by QxMD
47. Increased Intracranial Pressure. http://www.healthline.com/health/increased-intracranial-pressure#Overview1. Updated: October 22, 2015. Accessed: March 1, 2017.